May 17, 2024
In the year since the U.S. Supreme Court said "extraordinary" and "far-reaching" attacks on administrative enforcers can skip agency tribunals and go straight to federal district court, ambitious challenges to regulatory powers are rapidly gaining traction, and the high court is poised to put them on an even firmer footing.
August 29, 2023
The U.S. Chamber of Commerce is backing biotechnology company Amgen in its bid to complete a $27.8 billion merger with Horizon Therapeutics, saying in an amicus brief Tuesday that if the Federal Trade Commission succeeds with its current argument, the government could block any merger based on hypothetical concerns.
August 28, 2023
The Federal Trade Commission appears to be mulling a deal resolving its challenge to Amgen's planned $27.8 billion purchase of Horizon Therapeutics, publicly disclosing that the agency had pulled the case from its in-house docket — but not the federal docket — for "proper resolution."
August 22, 2023
Amgen and Horizon Therapeutics urged an Illinois federal judge not to let the Federal Trade Commission block their planned $27.8 billion merger, arguing in a brief unsealed Tuesday that FTC fears that the companies could anti-competitively protect Horizon drugs from rivals are entirely hypothetical and make no sense.
August 15, 2023
A deluge of trials and key hearings are slated for the coming weeks in antitrust cases spread across the country, including the first expected trials for monopolization claims against Google, trials in a variety of other conduct cases from enforcers and private parties, and hearings on several merger challenges.
August 11, 2023
Amgen and Horizon Therapeutics urged an Illinois federal judge Thursday to preserve their attacks on the constitutionality of the Federal Trade Commission and its in-house process as part of the agency challenge to their $27.8 billion merger, arguing those assertions "are plainly relevant" to the case.
July 21, 2023
Federal antitrust regulators moved Thursday to block pharmaceutical companies Amgen and Horizon from challenging the constitutionality of the Federal Trade Commission and its in-house process, at least for now, as they try to put a pause on the companies' nearly $28 billion merger.
July 20, 2023
A jury will decide appropriate damages for biometric privacy violations, federal antitrust regulators will put a relatively novel pharmaceutical theory to the test and nursing homes in the state will learn whether they'll need to tweak their contracts, as part of cases in Illinois worth watching for the rest of 2023.
July 17, 2023
The Federal Trade Commission has asked an Illinois federal court to issue a preliminary injunction preventing Amgen and Horizon Therapeutics from closing their planned $27.8 billion merger before an administrative case challenging the deal concludes.
June 30, 2023
Amgen and Horizon Therapeutics have filed counterclaims against the Federal Trade Commission in Illinois federal court, becoming the latest companies to attack the constitutionality of the agency's administrative process amid a merger challenge from the commission.